Validating the eating disorder inventory (EDI‐2) in two danish samples: A comparison between female eating disorder patients and females from the general population

The Eating Disorder Inventory, Version 2 (EDI‐2) is a questionnaire used clinically and in research all over the world. EDI‐2 is cross‐culturally valid, yet normative values may depend on culture. Norms and reliability of the Danish version have to date been lacking, and will be presented in this article, comparing patients (N = 575) and controls (N = 881). Also, internal reliability of scales is tested for both groups. Differences between norms of the Danish and the North American version of EDI were small but significant for all scales except asceticism (eating disorder patients) and ineffectiveness, interpersonal distrust and maturity fears (normal controls). For both groups the internal consistency was >0.70 for all subscales except asceticism. Although differences across the eating disorder diagnostic groups were dubious, the EDI‐2 is useful to screen for eating problems in the general population as well as to rate progress and outcome among eating disorder patients. Copyright © 2009 John Wiley & Sons, Ltd and Eating Disorders Association.     

Subclavian vein catheterization for acute and chronic haemodialysis. A safe temporary vascular access

The technique and use of a percutaneous subclavian vein catheter for haemodialysis in 20 patients are reported. The catheterization procedure carried a very low morbidity, and blood flow rates of 200–250ml/min were achieved through the catheters. Use of this angioaccess saves future possible sites for permanent vascular access. Infectious complications were not encountered. Subclavian vein catheterization is a favourable alternative to external Silastic Teflon shunt.     

Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism

Ingestion of cruciferous vegetables may prevent chemically inducedcarcinogenesis by their influence on specific cytochrome P450enzymes (CYP) and phase II drug metabolizing enzymes in humansand rodents. Thus CYP enzymes are involved in transformationof procarcinogens, mutagens, steroid hormones and a large varietyof other endogenous and exogenous components. In order to learnmore about the influence of cruciferous vegetables on drug metabolizingenzymes in man two CYP enzymespreviously suggested to be inducedby vegetables were selected in an in vivo experiment in humans.Sixteen healthy non-smoking subjects, two females and 14 males,were exposed to three different types of diets and afterwardsassayed for CYP1A2 catalysed caffeine metabolites and for CYP2E1catalysed 6-hydroxylation of chlorzoxazone. Further, 2-hydroxyoestrone:16     

The orthopan tomoscintigram — a new application of emission computed tomography for facial bone scanning

The exact regional correlation of findings of facial bone scans, planar or SPECT, to dental orthopan X-ray films (OPT) is difficult because of the very different projection techniques. To improve correlative imaging in this regard a projection algorithm was developed that uses SPECT data of the skull for reconstructing an orthopan tomoscintigraphic projection. Fourteen conventional SPECT slices of the upper and lower jaws were obtained during bone scanning. All mandibular slices were superimposed resulting in a horseshoe shaped structure, which was marked by an ROI which was divided into segments. All 14 SPECT slices were then masked by this segmental ROI, thereby marking the teeth-carrying bone in all slices. The information from this horseshoe like ROI is then transformed into lines. Line by line arrangement results in an orthopan projection, the orthopan tomoscintigram. This new display allows 1:1 true scale superimposition with the X-ray OPT and markedly facilitates correlative imaging.     

A simple and rapid method for the determination of the concentrations of magnesium, sodium, potassium and sodium, potassium pumps in human skeletal muscle

1. For the diagnosis of electrolyte disorders, data on skeletal muscle composition are often valuable, but rarely available. We have therefore developed a simple and rapid needle biopsy procedure for the determination of the concentrations of K+, Na+, Mg2+ and Na+, K+-pumps in muscle. 2. Using a Bergstr?m needle, biopsies weighing around 25 mg were taken from the vastus lateralis muscle of 18 normal subjects (aged 44-86 years) and extracted with trichloroacetic acid (TCA). The concentrations of K+, Na+ and Mg2+ were 90.7 +/- 1.8, 31.9 +/- 1.6 and 9.5 +/- 0.2 mumol/g wet wt., respectively (means +/- SE). 3. The TCA extraction gave the same values as digestion with 65% HNO3 or 35% H2O2, could be used over the weight range 10-55 mg and showed a Mg2+ recovery of 101.7%. 4. The concentration of Na+, K+-pumps was quantified as the total capacity for [3H]ouabain binding. In vastus lateralis biopsies obtained from six normal subjects the mean value was 258 +/- 16 pmol/g wet wt. 5. Comparison of the concentrations of K+, Mg2+ and [3H]ouabain-binding sites in samples obtained post mortem showed modest variation among different muscles with varying fibre composition. 6. Measurements of the concentrations of K+, Na+, Mg2+ and Na+, K+-pumps in duplicate biopsies of the vastus lateralis yield values which seen representative for the total pool of skeletal muscle fibres and can be performed within a few hours.(ABSTRACT TRUNCATED AT 250 WORDS)     

A study comparing biopharmaceutic characteristics of four once daily controlled release diltiazem preparations

Summary— In the present study we have compared the steady state biopharmaceutic characteristics of four diltiazem once daily controlled release capsules: Mono-Tildiem LP 300® (300 mg), Adizem® XL (300 mg)¹, Cardizem® (300 mg) and Dilacor® (240 mg). Sixteen healthy male volunteers (aged 22.9 ± 3.3 years, range 19–31 years) completed an open label, multiple oral dose, randomized, four-period crossover study without a washout period in between. The volunteers received each diltiazem formulation once daily for four days. Trough diltiazem and metabolites plasma concentrations were determined on days 3 and 4. The 24-h plasma concentration-time profiles were assessed after the dose on day 4 of each period. The following steady state pharmacokinetic parameters for diltiazem were calculated: the minimum plasma concentration (c_min), the maximum plasma concentration (c_max), the time to reach that concentration (t_max), the time interval during which the plasma concentration exceeds 50% of c_max (t₅₀), the area under the plasma concentration-time curve (AUC_72–96) and the peak-to-trough fluctuation (PTF). For the metabolites of diltiazem, N-mono-desmethyl-diltiazem (NDM) and desacetyldiltiazem (DAD), AUC_72–96 (AUC_NDM and AUC_DAD) and the ratio metabolite/parent compound were calculated. Steady state was achieved on day 3. Except one, all controlled release formulations have satisfactory controlled release properties allowing once daily administration. However, significant (P < 0.05) differences were found between the pharmacokinetic characteristics which do not allow exchange of the various formulations. Concentrations well below 50 ng·mL^-1 in the morning hours were observed for Dilacor® (240 mg) and Adizem® XL (300 mg), which could be a disadvantage of these formulations as it is well-known that ischaemic events occur at a higher rate during that part of the day. The plasma concentration profiles of NDM and DAD, the major circulating metabolites, parallel the plasma concentration profiles for the parent compound. From a clinical point of view, all treatments were well tolerated.